About ABION BIO
ABION BIO is a company based in Seoul (South Korea) founded in 2007. It operates as a HealthTech. ABION BIO has raised $10.77 million across 6 funding rounds from investors including Korea Investment Holdings, LB Investment and IMM Investment. The company has 44 employees as of December 31, 2024. ABION BIO offers products and services including ABN401 (Vabametkib), ABN501, and ABN101. ABION BIO operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Seoul, South Korea
- Employees 44 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abion Inc.
-
Annual Revenue
$515.06 K (USD)-40.38as on Dec 31, 2024
-
Net Profit
$-29.41 M (USD)-48.51as on Dec 31, 2024
-
EBITDA
$-24.42 M (USD)-17.68as on Dec 31, 2024
-
Total Equity Funding
$10.77 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
Korea Investment Holdings
& 2 more
-
Employee Count
44
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ABION BIO
ABION BIO is a publicly listed company on the KRX with ticker symbol 203400 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ABION BIO
ABION BIO offers a comprehensive portfolio of products and services, including ABN401 (Vabametkib), ABN501, and ABN101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted therapy for non-small cell lung cancer.
Antibody therapy targeting claudin3 for ovarian cancer.
Biobetter interferon beta for respiratory virus prevention.
Funding Insights of ABION BIO
ABION BIO has successfully raised a total of $10.77M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(01 Jan 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2015 | Amount | Grant - ABION BIO | Valuation |
investors |
|
| Jul, 2015 | Amount | Series A - ABION BIO | Valuation |
investors |
|
| Nov, 2014 | Amount | Series A - ABION BIO | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ABION BIO
ABION BIO has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, LB Investment and IMM Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth-stage private equity investments are targeted across multiple sectors.
|
Founded Year | Domain | Location | |
|
IMM Investment is recognized as a leading multi-asset alternative investment firm in Asia.
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ABION BIO
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ABION BIO
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abion Bio Comparisons
Competitors of ABION BIO
ABION BIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abion Bio
Frequently Asked Questions about ABION BIO
When was ABION BIO founded?
ABION BIO was founded in 2007 and raised its 1st funding round 6 years after it was founded.
Where is ABION BIO located?
ABION BIO is headquartered in Seoul, South Korea.
Is ABION BIO a funded company?
ABION BIO is a funded company, having raised a total of $10.77M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.86M, raised on Jan 01, 2013.
How many employees does ABION BIO have?
As of Dec 31, 2024, the latest employee count at ABION BIO is 44.
What is the annual revenue of ABION BIO?
Annual revenue of ABION BIO is $515.06K as on Dec 31, 2024.
What does ABION BIO do?
ABION BIO is focused on the development of innovative pharmaceuticals targeting best-in-class and first-in-class solutions for global markets. Oncology drugs like ABN401, a targeted therapy for non-small cell lung cancer, and ABN501, an antibody therapy for ovarian cancer, are researched and developed. Additionally, antiviral solutions such as ABN101, a biobetter for respiratory viruses, are advanced. Expansion into various solid tumors and pandemics prevention is pursued. Global clinical trials and commercialization are prioritized across multiple therapeutic areas.
Who are the top competitors of ABION BIO?
ABION BIO's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does ABION BIO offer?
ABION BIO offers ABN401 (Vabametkib), ABN501, and ABN101.
Is ABION BIO publicly traded?
Yes, ABION BIO is publicly traded on KRX under the ticker symbol 203400.
Who are ABION BIO's investors?
ABION BIO has 3 investors. Key investors include Korea Investment Holdings, LB Investment, and IMM Investment.
What is ABION BIO's ticker symbol?
The ticker symbol of ABION BIO is 203400 on KRX.